Results 21 to 30 of about 261,105 (346)

Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial

Gastric Cancer, 2021
Background In the phase 3 KEYNOTE-061 study (cutoff: 10/26/2017), pembrolizumab did not significantly prolong OS vs paclitaxel as second-line (2L) therapy in PD-L1 combined positive score (CPS) ≥ 1 gastric/GEJ cancer.
C. Fuchs, M. Özgüroğlu, Y. Bang, M. Di Bartolomeo, M. Mandalà, M. Ryu, L. Fornaro, T. Olesiński, C. Caglevic, H. Chung, K. Muro, E. Van Cutsem, A. Elme, P. Thuss-Patience, I. Chau, A. Ohtsu, P. Bhagia, Anran Wang, C. Shih, K. Shitara   +19 more
semanticscholar   +1 more source

Comparison of Peripheral Neuropathy Induced by Standard and Nanoparticle Albumin–Bound Paclitaxel in Rats

Journal of Pharmacological Sciences, 2011
.: Nanoparticle albumin–bound paclitaxel (nab-paclitaxel) is delivered to tumors and increases antitumor activity compared with solvent-based paclitaxel.
Yuji Yamashita, Nobuaki Egashira, Ken Masuguchi, Soichiro Ushio, Takehiro Kawashiri, Ryozo Oishi   +5 more
doaj   +1 more source

Chromosomal instability sensitizes patient breast tumors to multipolar divisions induced by paclitaxel

Science Translational Medicine, 2021
Description Paclitaxel cytotoxicity in breast tumors depends on multipolar spindle maintenance and preexisting chromosomal instability. Unpacking paclitaxel response Paclitaxel is a common treatment for many cancers, although not all patients benefit ...
Christina M. Scribano, Jun Wan, K. Esbona, John B. Tucker, A. Lasek, A. S. Zhou, Lauren M. Zasadil, Ryan Molini, J. Fitzgerald, Angela M. Lager, J. Laffin, Kayla Correia-Staudt, K. Wisinski, Amye J. Tevaarwerk, R. O'Regan, S. McGregor, A. Fowler, Richard J. Chappell, T. Bugni, M. Burkard, Beth A. Weaver   +20 more
semanticscholar   +1 more source

miR-17-5p downregulation contributes to paclitaxel resistance of lung cancer cells through altering beclin1 expression. [PDF]

PLoS ONE, 2014
Non-small-cell lung cancer (NSCLC) is one of the most leading causes of cancer-related deaths worldwide. Paclitaxel based combination therapies have long been used as a standard treatment in aggressive NSCLCs.
Abhisek Chatterjee, Dhrubajyoti Chattopadhyay, Gopal Chakrabarti   +2 more
doaj   +1 more source

Prodrug Strategies for Paclitaxel [PDF]

International Journal of Molecular Sciences, 2016
Paclitaxel is an anti-tumor agent with remarkable anti-tumor activity and wide clinical uses. However, it is also faced with various challenges especially for its poor water solubility and low selectivity for the target. To overcome these disadvantages of paclitaxel, approaches using small molecule modifications and macromolecule modifications have ...
Xiaoqing Lv, Ziyuan Meng, Jun Lu, Quanxia Lv, Feng Jiang, Feng Jiang, Ge Zhang, Aiping Lu, Houzong Yao   +8 more
openaire   +2 more sources

Atezolizumab and Nab‐Paclitaxel in Advanced Triple‐Negative Breast Cancer

New England Journal of Medicine, 2018
Background Unresectable locally advanced or metastatic triple‐negative (hormone‐receptor–negative and human epidermal growth factor receptor 2 [HER2]–negative) breast cancer is an aggressive disease with poor outcomes.
P. Schmid, S. Adams, H. Rugo, A. Schneeweiss, C. Barrios, H. Iwata, V. Diéras, R. Hegg, S. Im, G. Shaw Wright, V. Henschel, L. Molinero, S. Chui, R. Funke, A. Husain, E. Winer, S. Loi, L. Emens   +17 more
semanticscholar   +1 more source

Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209).

Journal of Clinical Oncology, 2020
PURPOSE Limitations of the paclitaxel-doxorubicin-cisplatin (TAP) regimen in the treatment of endometrial cancer include tolerability and cumbersome scheduling.
D. Miller, V. Filiaci, R. Mannel, D. Cohn, Takashi Matsumoto, K. Tewari, P. DiSilvestro, M. Pearl, P. Argenta, M. Powell, S. Zweizig, D. Warshal, P. Hanjani, M. Carney, Helen Q. Huang, D. Cella, R. Zaino, G. Fleming   +17 more
semanticscholar   +1 more source

CPEB4-Promoted Paclitaxel Resistance in Ovarian Cancer In Vitro Relies on Translational Regulation of CSAG2

Frontiers in Pharmacology, 2021
Background: Drug resistance is a major obstacle in chemotherapy for ovarian cancer, wherein the up regulation of drug-resistant genes plays an important role.
Yaqing Zhang, Hongyun Gan, Fei Zhao, Xiaomei Ma, Xiaofeng Xie, Rui Huang, Jin Zhao   +6 more
doaj   +1 more source

Pharmacogenomics of Paclitaxel [PDF]

Pharmacogenomics, 2010
The microtubule-stabilizing drug paclitaxel is a cytotoxic agent widely used for the treatment of a variety of tumor types. Since its introduction to the clinic, modifications to the administration schedule and treatments for hypersensitivity reactions and neutropenia have significantly improved paclitaxel therapy.
openaire   +2 more sources

Paclitaxel’s Mechanistic and Clinical Effects on Breast Cancer

Biomolecules, 2019
Paclitaxel (PTX), the most widely used anticancer drug, is applied for the treatment of various types of malignant diseases. Mechanisms of PTX action represent several ways in which PTX affects cellular processes resulting in programmed cell death.
Tala M Abu Samaan, Marek Samec, A. Líšková, P. Kubatka, Dietrich Büsselberg   +4 more
semanticscholar   +1 more source